✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Jagsonpal Pharmaceuticals Ltd.

JAGSNPHARM

Market Cap
₹1,589 Cr.
P/E
30.37

Jagsonpal Pharmaceuticals Ltd.

  • Jagsonpal Pharma
  • Syncom Formulations
  • Bliss GVS Pharma
FAQs on Jagsonpal Pharmaceuticals Ltd. Shareprice

Jagsonpal Pharma has given better returns compared to its competitors.
Jagsonpal Pharma has grown at ~52.24% over the last 7yrs while peers have grown at a median rate of 10.65%

Jagsonpal Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Jagsonpal Pharma is 28.45, while 3 year average PE is 36.67.
Also latest EV/EBITDA of Jagsonpal Pharma is 31.34 while 3yr average is 26.19.

View FAQ's On Business
Growth Table
  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma
Balance Sheet
  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma
Cash Flow
  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma
Quarterly Results
  • Jagsonpal Pharmaceuticals Ltd.
  • Syncom Formulations
  • Bliss GVS Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Jagsonpal Pharmaceuticals Ltd. Financials

Balance sheet of Jagsonpal Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Jagsonpal Pharma is increasing.
Latest debt of Jagsonpal Pharma is -₹77.84 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹295.87 Crs.

The profit is oscillating.
The profit of Jagsonpal Pharma is ₹52.33 Crs for TTM, ₹22.46 Crs for Mar 2024 and ₹26.72 Crs for Mar 2023.

The company seems to pay a good stable dividend.
Jagsonpal Pharma latest dividend payout ratio is 58.85% and 3yr average dividend payout ratio is 54.48%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech